GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Obes Surg (2008) 18(9):11837
The new GLP-1 RA users, SGLT-2 inhibitor users and DPP-4 inhibitor users were defined as a first-time redemption for prescription of drugs with anatomical therapeutic chemical (ATC) codes A10BJ (GLP-1), A10BH (DPP-4 inhibitors) or A10BK (SGLT-2 inhibitors)
While these medications show favorable outcomes in HbA1c reduction and weight loss, cost and tolerability remain significant barriers to widespread use
Programs frequently run promos and change pricing tiers, so always confirm at checkout
%25201.png)
